scholarly journals In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide

2009 ◽  
Vol 76 (4) ◽  
pp. 437-444 ◽  
Author(s):  
Nosratola D. Vaziri ◽  
Hamid Moradi ◽  
Madeleine V. Pahl ◽  
Alan M. Fogelman ◽  
Mohamad Navab
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Inflammatory Activity ◽  
Mimetic Peptide ◽  
Anti Inflammatory ◽  
Stage Renal Disease ◽  
End Stage ◽  
Stimulation Of

scholarly journals Case-control study of regular analgesic and nonsteroidal anti-inflammatory use and end-stage renal disease

2005 ◽  
Vol 67 (6) ◽  
pp. 2393-2398 ◽  
Author(s):  
Luisa Ibeiez ◽  
Merius Morlans ◽  
Xavier Vidal ◽  
Marea Jose Martanez ◽  
Joan-Ramon Laporte
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Case Control Study ◽  
Case Control ◽  
Anti Inflammatory ◽  
Stage Renal Disease ◽  
End Stage ◽  
Control Study

Differences between KT/V Measured during Dialysis and KT/V Predicted from Manufacturer Clearance Data

1992 ◽  
Vol 15 (8) ◽  
pp. 465-469 ◽  
Author(s):  
L.K. Saha ◽  
J.C. Van Stone
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Urea Clearance ◽  
Blood Flows ◽  
The Mean ◽  
Stage Renal Disease ◽  
End Stage

We retrospectively analyzed data from 3,863 dialysis treatments in 329 end-stage renal disease patients over a period of 33 months to evaluate the accuracy of in vitro KT/V estimated by manufacturer's urea clearance data in relation to in vivo measured KT/V. In 1,087 urea clearances measured, mean actual clearance was 87% of predicted. At all blood flows, actual clearances were significantly lower than predicted (8-16% lower than predicted). In 2,807 KT/V measurements, predicted KT/V was 1.238 ± 0.005 whereas the mean of actual measured KT/V was 16% lower or 1.024 ± 0.005 (P < 0.0001). At different blood flows and with different dialyzers, predicted KT/V overestimated actual values. With increasing numbers of reuse, actual/predicted clearance ratios and actual/predicted KT/V ratios progressively dropped. Prescribing dialysis treatments using manufacturer's in vitro generated clearance data can lead to marked underdialysis of patients.

Lupus-Like in vitro Anticoagulant Activity in End-Stage Renal Disease

Nephron ◽  
1988 ◽  
Vol 49 (1) ◽  
pp. 39-44 ◽  
Author(s):  
Carlos Quereda ◽  
Ana Pardo ◽  
Santiago Lamas ◽  
Luis Orofino ◽  
Angel Carcía-Avello ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Anticoagulant Activity ◽  
Stage Renal Disease ◽  
End Stage

Endothelial Microparticles and Their Binding to Leukocytes in Patients with End-Stage Renal Disease.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 3939-3939
Author(s):  
David Zuckerman ◽  
Mark Hofmeyer ◽  
Julio A. Chirinos ◽  
Wenche Jy ◽  
Joaquin J. Jimenez ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Neutrophil Activation ◽  
In Vitro Studies ◽  
Cd11b Expression ◽  
Endothelial Microparticles ◽  
Stage Renal Disease ◽  
End Stage ◽  
Normal Controls

Abstract Background: End-stage renal disease (ESRD) has been associated with endothelial dysfunction, a proinflammatory state and markedly increased cardiovascular risk. Endothelial microparticles (EMP) are released by activated or apoptotic endothelial cells. In vitro studies have shown that EMP can bind and activate neutrophils, suggesting that they may represent not only markers of endothelial status but also mediators of inflammation. The objectives of this study were to: Assess the levels of free EMP and leukocyte-bound EMP in ESRD; Determine whether EMP binding to neutrophils predicts the degree of neutrophil activation in patients with ESRD. Methods: We measured the levels of endothelial microparticles (EMP) and EMP-leukocyte conjugates in 80 patients with ESRD and 35 normal controls. We performed flow cytometry in peripheral venous blood before hemodialysis to measure (1) EMP positive for CD31 (EMP31), E-selectin (EMP62E), CD54 (EMP54); (2) EMP54- and EMP62E-leukocyte conjugates; (3) Neutrophil activation, assessed by expression of activation marker CD11b. Results: Assessment of free EMP revealed that patients with ESRD had slightly elevated levels of free EMP54 but not of free EMP62E or EMP31. However, levels of EMP54-Lymphocyte, EMP54-Monocyte, EMP54-Neutrophil, EMP62E-Lymphocyte and EMP62E-Monocyte conjugates were clearly elevated in patients with ESRD. CD11b expression in leukocytes strongly correlated with levels of EMP54-Neutrophil conjugates (R=0.67; p&lt;0.0001) and EMP62E-Neutrophil conjugates (R=0.66; p&lt;0.0001). Furthermore, both types of conjugates independently predicted CD11b expression (adjusted p&lt;0.05). Conclusions: ESRD is associated with increased binding of EMP to leukocytes, resulting in normal levels of some species of free EMP. Therefore, measurement of both free EMP and EMP-leukocyte conjugates is necessary for adequately assessing EMP release in ESRD. Levels of EMP bound to neutrophils strongly predict neutrophil activation, suggesting that EMP induce neutrophil activation in vivo, consistent with in vitro studies. EMP may represent important mediators of the proinflammatory state in ESRD. EMP and EMP-Leukocyte Conjugates in ESRD patients compared to normal controls ESRD (n=80) Controls (n=35) P value IQR=Interquartile range EMP31 (IQR) 842 (484–1546) 807 (566–1240) 0.97 EMP62E (IQR) 69 (39–128) 60 (43–113) 0.96 EMP54 (IQR) 75 (33–144) 34 (18–141) 0.04 EMP54-Lymphocyte Conjugates (±SD) 1.45±0.2 1.21±0.1 &lt;0.0001 EMP54-Monocyte Conjugates (±SD) 1.77±0.6 1.27±0.3 &lt;0.0001 EMP54-Neutrophil Conjugates (±SD) 2.12±0.6 1.85±0.6 0.02 EMP62E-Lymphocyte Conjugates (±SD) 1.30±0.2 1.13±0.1 &lt;0.0001 EMP62E-Monocyte Conjugates (±SD) 1.61±0.5 1.40±0.3 0.01 EMP62E-Neutrophil Conjugates (±SD) 2.04±0.6 2.05±0.5 0.95

Sign in / Sign up

Export Citation Format

Share Document